Global Amyotrophic Lateral Sclerosis Therapeutics Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Amyotrophic Lateral Sclerosis Therapeutics market size will reach US$ 415 million by 2031.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person"s parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person"s signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
LPI (LP Information)' newest research report, the “Amyotrophic Lateral Sclerosis Therapeutics Industry Forecast” looks at past sales and reviews total world Amyotrophic Lateral Sclerosis Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis Therapeutics sales for 2025 through 2031. With Amyotrophic Lateral Sclerosis Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amyotrophic Lateral Sclerosis Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Riluzole
Edaravone (Radicava)
Other
Segmentation by Application:
Hospital
Drugs Store
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Please note: The report will take approximately 2 business days to prepare and deliver.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person"s parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person"s signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
LPI (LP Information)' newest research report, the “Amyotrophic Lateral Sclerosis Therapeutics Industry Forecast” looks at past sales and reviews total world Amyotrophic Lateral Sclerosis Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis Therapeutics sales for 2025 through 2031. With Amyotrophic Lateral Sclerosis Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amyotrophic Lateral Sclerosis Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Riluzole
Edaravone (Radicava)
Other
Segmentation by Application:
Hospital
Drugs Store
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
96 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Amyotrophic Lateral Sclerosis Therapeutics Market Size by Player
- 4 Amyotrophic Lateral Sclerosis Therapeutics by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Amyotrophic Lateral Sclerosis Therapeutics Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
